1
Return

Safety of the use of an absorbable implant in breast-conserving surgery followed by radiotherapy: preplanned interim results from a prospective study

delete2026-04-01
delete0
PRE
AI
M
Mariniello, Maria Donatella *
L
Lisa, Andrea Vittorio Emanuele
M
Montrone, Sabrina
L
Leonardi, Maria Cristina
M
Mazzotta, Dionisia
B
Bottoni, Manuela
M
Mattia Intra
T
Tamplenizza, Margherita
G
Gerges, Irini
D
Diaz, Inma
A
Acea, Benigno
DOI:10.1007/s13304-026-02629-3delete
deleteOriginal
deleteOriginal request for help
deleteShare
deleteSave
Abstract

Abstract

En 中文
Oncoplastic techniques aim to optimize cosmetic and oncologic results after BCS. Absorbable scaffolds may aid volume replacement while preserving radiotherapy (RT) planning and follow-up imaging, though clinical evidence remains limited. This interim analysis of a prospective, multicenter, single-arm trial (Tens-BBC/003/2021; NCT05941299) included 25 patients with 6 month follow-up after BCS and whole-breast RT. Outcomes were adverse events (AEs), device usability, pain (VAS), satisfaction, quality of life (BREAST-Q (c)), cosmetic and imaging results, and RT tolerance. Mean age was 53.6 years, BMI 24.8 kg/m(2). Tumors were mainly in the upper-outer quadrant (52%); T1c in 56%, T1b in 20%, T2 in 24%. Histology was invasive ductal carcinoma in 72%, nodal status cN0 in 96%. Mean surgery time was 74.7 min; drains were used in 76%. REGENERA (TM) type A (70 mL) was implanted in 84%, type B (100 mL) in 16%. No major complications occurred. Of 94 AEs within 90 days, all were mild/moderate and unrelated to the device; four later AEs (in one patient) were possibly implant-related. Investigator satisfaction (VAS) improved from 8.4 at implantation to 9.2 at 6 months; usability targets were exceeded. Pain decreased from 2.3 to 1.56. BREAST-Q (c) showed higher breast satisfaction (+ 8.9, p = 0.041), reduced distress (-10.3, p = 0.006), and a modest decline in physical well-being (-11.6, p = 0.012). All patients completed RT; acute toxicity occurred in 44%, all grade 1-2. Cosmetic outcomes were good to excellent in 88%. Radiological integration was satisfactory, with no significant interference in MRI. REGENERA (TM) is safe, feasible, and biocompatible for volume replacement in BCS. It provides high satisfaction and favorable cosmetic results without compromising RT or follow-up imaging. Early results support its integration into oncoplastic practice, though long-term evaluation is required.
Keywords:
Breast-conserving surgery
Absorbable scaffold
Polyurethane
REGENERA (TM)
Breast cancer
Oncoplastic
Interim analysis

Journal

U
Updates in Surgery
IF:
2.2
Papers:
230
Citations:
3.1K

Organization

C
complejo hospitalario universitario a coruna
Scholars:
161
Papers: 87
Citations: 0
U
Universidade da Coruña
Scholars:
335
Papers: 150
Citations: 4.8K
I
irccs european institute of oncology (ieo)
Scholars:
7.4K
Papers: 4.6K
Citations: 2
A
Azienda Ospedaliero Universitaria Pisana
Scholars:
4.2K
Papers: 3.2K
Citations: 15
U
university of pisa
Scholars:
3.6K
Papers: 1.4K
Citations: 0
U
University of Rome Tor Vergata
Scholars:
2.5W
Papers: 1.8W
Citations: 2.0W
Cited Papers

Cited Papers

Citing Papers

Citing Papers